Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Keith Komar for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Komar was convicted of one felony count under Federal law for mail fraud. The factual basis supporting Mr. Komar's conviction, as described below, is conduct relating to the importation into the United States of a drug or controlled substance. Mr. Komar was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of 30 days after receipt of the notice (July 22, 2020), Mr. Komar had not responded. Mr. Komar's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.
This order is applicable October 20, 2020.
Submit applications for termination of debarment to the Dockets Management Staff, Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
Start Further Info
FOR FURTHER INFORMATION CONTACT:
Jaime Espinosa, Division of Enforcement, Office of Strategic Planning and Operational Policy, Office of Regulatory Affairs, Food and Drug Administration, 12420 Parklawn Dr., Rockville, MD 20857, 240-402-8743, or at firstname.lastname@example.org.
End Further Info
Start Supplemental Information
Section 306(b)(1)(D) of the FD&C Act (21 U.S.C. 335a(b)(1)(D)) permits debarment of an individual from importing or offering for import any drug into the United States if FDA finds, as required by section 306(b)(3)(C) of the FD&C Act, that the individual has been convicted of a felony for conduct relating to the importation into the United States of any drug or controlled substance. On November 7, 2019, Mr. Komar was convicted, as defined in section 306(l)(1) of the FD&C Act, in the U.S. District Court for the Western District of Pennsylvania, when the court entered judgment against him for the felony offense of mail fraud in violation of 18 U.S.C. 1341.
FDA's finding that debarment is appropriate is based on the felony conviction referenced herein. The factual basis for this conviction is as follows: As contained in count 3 of the indictment in Mr. Komar's case, filed on November 29, 2017, to which Mr. Komar pleaded guilty, on or about December 7, 2015, Mr. Komar, for the purpose of executing a scheme and artifice to defraud, and in attempting to do so, knowingly caused the U.S. mail to deliver from Mumbai, India, a parcel containing misbranded drugs. Specifically, the parcel contained 30 tablets of the unapproved new prescription drug bicalutamide and 30 gelcaps of the unapproved new prescription drug isotretinoin. These drugs were misbranded because, as contained in the indictment in Mr. Komar's case, they were dispensed to consumers without a valid prescription from a practitioner licensed by law to administer such drugs, and they did not contain labeling bearing adequate directions for use. As detailed in facts contained in counts 1, 2, and 4 of Mr. Komar's indictment (facts which Mr. Komar acknowledged responsibility for in his plea agreement), Mr. Komar was part of a criminal conspiracy. As part of this criminal conspiracy, Mr. Komar's intent was to fraudulently import this misbranded bicalutamide and isotretinoin and sell them in interstate commerce to customers of Mr. Komar's websites. On these websites Mr. Komar made a number of false statements to potential customers, such as that he provided “high quality, safe, and approved medications meeting or exceeding the U.S. FDA standard.” In addition, Mr. Komar later did in fact cause the introduction and delivery for introduction of misbranded drugs (bicalutamide and isotretinoin) into interstate commerce with the intent to defraud and mislead by selling these unapproved new prescription drugs to a Start Printed Page 66569customer who did not have a prescription for them. A member of the conspiracy caused the customs declaration on the parcel to falsely report that the parcel contained a health product sample with no declared value.
As a result of this conviction, FDA sent Mr. Komar, by certified mail on June 11, 2020, a notice proposing to debar him for a 5-year period from importing or offering for import any drug into the United States. The proposal was based on a finding under section 306(b)(3)(C) of the FD&C Act that Mr. Komar's felony conviction for one felony count under Federal law for mail fraud was for conduct relating to the importation into the United States of any drug or controlled substance because he illegally caused bicalutamide and isotretinoin to be introduced in interstate commerce from Mumbai, India, by selling to a consumer who did not have a prescription through the U.S. mail in violation of 18 U.S.C. 1341.
In proposing a debarment period, FDA weighed the considerations set forth in section 306(c)(3) of the FD&C Act that it considered applicable to Mr. Komar's offenses and concluded that this felony offense warranted the imposition of a 5-year period of debarment. The proposal informed Mr. Komar of the proposed debarment and offered Mr. Komar an opportunity to request a hearing, providing him 30 days from the date of receipt of the letter in which to file the request, and advised him that failure to request a hearing constituted a waiver of the opportunity for a hearing and of any contentions concerning this action. Mr. Komar received the proposal and notice of opportunity for a hearing on June 22, 2020. Mr. Komar failed to request a hearing within the timeframe prescribed by regulation and has, therefore, waived his opportunity for a hearing and waived any contentions concerning his debarment (21 CFR part 12).
II. Findings and Order
Therefore, the Assistant Commissioner, Office of Human and Animal Food Operations, under section 306(b)(3)(C) of the FD&C Act, under authority delegated to the Assistant Commissioner, finds that Mr. Keith Komar has been convicted of a felony under Federal law for conduct relating to the importation into the United States of any drug or controlled substance. FDA finds that the offense should be accorded a debarment period of 5 years as provided by section 306(c)(2)(A)(iii) of the FD&C Act.
As a result of the foregoing finding, Mr. Komar is debarred for a period of 5 years from importing or offering for import any drug into the United States, effective (see DATES). Pursuant to section 301(cc) of the FD&C Act (21 U.S.C. 331(cc)), the importing or offering for import into the United States of any drug or controlled substance by, with the assistance of, or at the direction of Mr. Komar is a prohibited act.
Any application by Mr. Komar for termination of debarment under section 306(d)(1) of the FD&C Act should be identified with Docket No. FDA-2020-N-1058 and sent to the Dockets Management Staff (see ADDRESSES). The public availability of information in these submissions is governed by 21 CFR 10.20(j).
Publicly available submissions will be placed in the docket and will be viewable at https://www.regulations.gov or at the Dockets Management Staff (see ADDRESSES) between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.
End Supplemental Information
Dated: October 13, 2020.
Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.
[FR Doc. 2020-23135 Filed 10-19-20; 8:45 am]
BILLING CODE 4164-01-P